نتایج جستجو برای: radioimmunoscintigraphy

تعداد نتایج: 74  

Journal: :Annals of the Academy of Medicine, Singapore 2003
Y H Ho L L P J Ooi

Considerable improvements in the survival and outcome of colorectal carcinoma have been made in recent years. These have been the result of advances in investigations, intervention as well as in follow-up management. Research continues in the laboratory, where significant discoveries and innovations pave the way for future progress. This issue highlights some of these exciting areas with invite...

2006
A. H. G. J. Schrijvers Jasper J. Quak Anne M. Uyterlinde Marijke van Walsum Chris J. L. M. Meijer Gordon B. Snow Guus A. M. S. van Dongen

Using viable cells of a human head and neck squamous cell carcinoma (HNSCC) cell line as immunogen, we developed monoclonal antibody (MAb) U36. Immunohistochemical examination revealed distinct surface labeling of MAb U36 with normal human squamous epithelium and squa mous cell carcinomas of distinct sites of origin; head and neck, lung, esophagus, cervix, and epidermis. MAb U36 shows high affi...

2000
Joep W. G. Stroomer Jan C. Roos Marlies Sproll Jasper J. Quak Karl-Heinz Heider Bram J. Wilhelm Jonas A. Castelijns Reiner Meyer Marthin O. Kwakkelstein Gordon B. Snow Günther R. Adolf Guus A. M. S. van Dongen

The CD44 protein family consists of isoforms, encoded by standard exons and up to nine alternatively spliced variant exons (v2–v10), which are expressed in a tissue-specific way. Expression of v6-containing variants (CD44v6) has been related to aggressive behavior of various tumor types and was shown to be particularly high in squamous cell carcinoma (SCC). Therefore, CD44v6 might be a suitable...

2005
Chaitanya R. Divgi Neil H. Bander Andrew M. Scott Joseph A. O’Donoghue George Sgouros Sydney Welt Ronald D. Finn Francesca Morrissey Peter Capitelli Jeanne M. Williams Devie Deland Aparna Nakhre Egbert Oosterwijk Seza Gulec Martin C. Graham Steven M. Larson

This Phase 1111 radioimmunotherapy study was carried out to determine the maximum tolerated dose (MTD) and therapeutic potential of ‘31I-G250. Thirty-three patients with measurable metastatic renal cell carcinoma were treated. Groups of at least three patients received escalating amounts of ‘ ‘I (30, 45, 60, 75, and 90 mCi/m2) labeled to 10 mg of mouse monoclonal antibody G250, administered as ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید